Products & Portfolio (5)
AMMONIA N 13
ammonia n-13
Post-LOE
INTRAVENOUS · INJECTABLE
Radiopharmaceutical Activity
2015
30
BORTEZOMIB
bortezomib
Post-LOE
INTRAVENOUS, SUBCUTANEOUS · INJECTABLE
chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.
myelomalymphoma
2025
30
FLUDEOXYGLUCOSE F18
fludeoxyglucose f-18
Post-LOE
INTRAVENOUS · INJECTABLE
Radiopharmaceutical Activity
2015
30
FLUDEOXYGLUCOSE F18
fludeoxyglucose f-18
Post-LOE
INTRAVENOUS · INJECTABLE
Radiopharmaceutical Activity
2015
30
SODIUM FLUORIDE F-18
sodium fluoride f-18
Post-LOE
INTRAVENOUS · INJECTABLE
2015
30
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Portfolio: 5 approved products
Top TAs: Oncology
H-1B (2023): 4 approvals
Portfolio Health
Post-LOE5 (100%)
5 total products
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
4
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub